We have recently demonstrated that potent inhibitors of BCL2 pro-survival family proteins significantly inhibit LSC survival, at doses that spare normal hematopoietic progenitors in BC CML (Goff et al., unpublished results). This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.